French Industry Loses Appeal Against Standardized OTC Packaging And Curb On Branding
Executive Summary
France's highest court rules that recommendations by the national drug regulator in favor of standardized packaging for OTC drugs - including reducing prominence of brand names - and curbing the practice of umbrella branding will continue to stand after rejecting an appeal by local industry association Afipa.
You may also be interested in...
French OTC Industry Frustrated By Regulatory Clampdown in 2019
Speaking exclusively to HBW Insight, French OTC association Afipa reflects on a difficult 2019 which saw tighter restrictions introduced on the sale of popular consumer health products. The trade group believes the industry's best prospects for a brighter future are rebuilding relations with national drug regulator ANSM and to getting self-care higher up the agenda of the French government.
Zantac Recall And EU Regulatory Issues Hurt Sanofi In Q3
Recalling Zantac in North America over contamination concerns and tightening regulatory requirements in Europe combined to impede growth at Sanofi Consumer Healthcare in Q3. New CEO Paul Hudson says he is still taking time to get to know the business before making any strategic moves.
French OTC Industry Warns Over-Regulation Is Threatening Its Future
Plans to move ibuprofen, aspirin and paracetamol OTCs behind the counter in French pharmacies will harm the country's self-medication industry, which is already lagging behind its European neighbors, warns local association Afipa.